Amgen owes $406 million for monopolizing cholesterol drug market, US jury says A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...